Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

Nearly a year and a half after Covid vaccines became available to adults in the U.S., the FDA has authorized two vaccines for ...

Moderna (NasdaqGS:MRNA) experienced a 10% share price increase, coinciding with broader market gains but slightly below the Nasdaq Composite's 5% rise. Despite the market being uplifted by strong ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

Moderna could bounce back from its tumble thanks to a rich pipeline of potential mRNA vaccines. Regeneron's top-selling drug and strong candidates should help it offset biosimilar competition. What ...

FRIDAY, April 25, 2025 (HealthDay News) -- On Tuesday, the U.S. Department of Health and Human Services announced that the government will invest $176 million in Moderna to expedite the creation of a ...

In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an ...

BofA lowered the firm’s price target on Moderna (MRNA) to $26 from $32 and keeps an Underperform rating on the shares. For 2025, the firm’s ...

Bernstein lowered the firm’s price target on Moderna (MRNA) to $28 from $39 given recent political headwinds for the stock, while keeping a ...

James Willhite was an editor with The Wall Street Journal's money & investing team based in London.

The pharmaceutical giant claims that Gutierrez Co. failed to properly design and build its manufacturing facility in Marlborough, Massachusetts.

As a result, Moderna's shares have suffered, falling more than 90% since their peak in 2021. Now let's consider where Moderna will be a few years from now. The company recently said it aims to ...